Upgrade to SI Premium - Free Trial

Guggenheim Reiterates Buy Rating on Merck (MRK)

April 9, 2026 7:09 AM
Guggenheim analyst Vamil Divan reiterated a Buy rating and $140.00 price target on Merck (NYSE: MRK).The analyst commented: "We are ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments